Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
11%(1 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
1
10%
Ph phase_1
9
90%

Phase Distribution

9

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
9(90.0%)
Phase 2Efficacy & side effects
1(10.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(9)
Terminated(1)

Detailed Status

Completed9
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
90.0%
Most Advanced
Phase 2

Trials by Phase

Phase 19 (90.0%)
Phase 21 (10.0%)

Trials by Status

completed990%
terminated110%

Recent Activity

Clinical Trials (10)

Showing 10 of 10 trials
NCT02322021Phase 2

Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease

Terminated
NCT02859207Phase 1

A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects

Completed
NCT03055962Phase 1

Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects

Completed
NCT01600859Phase 1

Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)

Completed
NCT01975636Phase 1

An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects

Completed
NCT02055703Phase 1

A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil

Completed
NCT01511783Phase 1

Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of E2609 in Healthy Subjects

Completed
NCT02207790Phase 1

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

Completed
NCT02222324Phase 1

A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects

Completed
NCT01716897Phase 1

An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10